GreyBird Ventures

GreyBird Ventures operates as an early-stage venture capital firm, dedicating its investments to diagnostic technologies within the precision medicine landscape. The firm focuses on identifying and supporting companies that develop solutions for critical diagnostic problems, thereby accelerating the advancement of tailored medical treatments. Its strategic approach emphasizes the fundamental role of precise disease identification as the necessary precursor for effective therapeutic interventions.

The firm was co-founded by Tom Miller, Michael Devlin, and Scott Gazelle, bringing together diverse yet complementary expertise. Tom Miller contributes a background as an experienced med-tech CEO and co-founder of LightLab Imaging, alongside training in medical physics. Michael Devlin is an international investment professional and lawyer, while Scott Gazelle is a physician-scientist and Harvard Professor who established the MGH Institute for Technology Assessment. Their collective insight highlighted the essential link between accurate diagnosis and successful patient outcomes.

GreyBird Ventures actively partners with entrepreneurs committed to developing these diagnostic innovations. The firm’s vision is to foster technologies that offer significant humanitarian benefits in healthcare, alongside generating financial returns, underpinned by a strong ethical commitment. They aim to support ventures that enhance diagnostic capabilities globally, ultimately serving a broad spectrum of healthcare providers and patients.